Development of Budesonide Loaded Biopolymer Based Dry Powder Inhaler: Optimization, In Vitro Deposition, and Cytotoxicity Study

Table 2

Characterization of in vitro deposition of formulations by TSI.

Formulation number	𝐷[0.9] [𝜇m]^a	Entrapment; efficiency [%]^a	Recovered; dose [𝜇g]^a	Fine particle; dose [𝜇g]^a	Respirable fraction [𝜇g]^a
F1	1.761 ± 0.05	80.68 ± 2.68	123.80 ± 0.04	52.15 ± 0.02	42.12 ± 0.02
F2	1.192 ± 0.03	86.43 ± 1.15	116.28 ± 0.02	48.84 ± 0.01	42.00 ± 0.03
F3	2.147 ± 0.03	90.92 ± 2.21	112.15 ± 0.03	44.87 ± 0.04	40.00 ± 0.01
F4	3.204 ± 0.01	85.94 ± 2.12	110.6 ± 0.06	44.24 ± 0.06	40.00 ± 0.05
F5	1.926 ± 0.03	86.66 ± 1.25	130.28 ± 0.04	51.81 ± 0.03	39.76 ± 0.02
F6	3.424 ± 0.04	92.64 ± 2.12	129.41 ± 0.03	47.51 ± 0.02	36.71 ± 0.04
F7	1.937 ± 0.06	87.16 ± 1.11	139.41 ± 0.03	60.09 ± 0.01	43.10 ± 0.02
F8	1.537 ± 0.08	91.39 ± 1.98	97.86 ± 0.01	29.75 ± 0.02	30.40 ± 0.03
F9	3.218 ± 0.09	92.20 ± 2.25	66.06 ± 0.04	30.03 ± 0.03	37.50 ± 0.01
Commercial DPI	—	—	48.31 ± 0.03	10.82 ± 0.03	22.39 ± 0.05

(+1) = higher values and (−1) = lower values.
aAll the determinations performed in triplicate and values are expressed as mean (values = average ± SD).